Navigation Links
Hope For Patients With Inflammatory Bowel Disease

Researchers say they may have discovered a potential form of relief for patients with inflammatory bowel disease.//

More than 1 million Americans are estimated to have ulcerative colitis or Crohn’s disease the two major forms of inflammatory bowel disease. The conditions, can be painful and debilitating, and can cause chronic inflammation of the digestive tracts. Patients with inflammatory bowel disease suffer bouts of watery diarrhea and abdominal pain and there is no known medical cure for either ulcerative colitis or Crohn’s disease, although medications can help symptoms.

Recent research has shown that anti-inflammatory therapy has offered relief in mouse models of Crohn’s disease and ulcerative colitis hence researchers explored how an immune system molecule called Toll-like receptor 9 could ease inflammation. Agents that activate Toll-like receptor 9, or TLR9, were given to two different groups of mice that appeared similar but were from different genetic strains. Reactions were different in the two strains of mice. The TLR9 activators inhibited the severity of experimental colitis but had no effect on the other group of mice.

To understand why the mice reacted differently, researchers used a variety of approaches to explore why one strain responded to therapy, and the other was resistant. They determined the TLR9-induced protection occurs when proteins called type 1 IFN-alpha and IFN-beta were activated. Thus researchers say based on their findings type 1 IFN-alpha and IFN-beta has a very important protective and potential therapeutic role .
'"/>




Page: 1

Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Amphetamines Help Recovery of Stroke Patients
3. Painkillers Do Not Shorten Dying Patients Lives
4. Patients With Filariasis More Prone To HIV Infection
5. Glivec - New Hope For CMC Patients
6. Patients often assume wrongly that they are allergic to penicillin
7. New FDA Approved Drug NATRECOR For Heart Failure Patients
8. Hemochromatosis Patients Blood is Safe
9. Patients Pressure Would Result In Overprescription
10. Risk Of Decongestants In Hypertensive Patients
11. Interference helps Heart Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... , ... Goodcents Deli Fresh Subs today announced the opening of a new ... St. Topeka, Kan. 66604 (near 21st and Gage). It is owned and operated by ... locations in the Topeka and Bonner Springs, Kan. area. , “Goodcents has such ...
(Date:6/23/2017)... ... June 23, 2017 , ... 21 Middle East and ... has selected 21 leaders from government, business and civil society in 11 countries across ... U.S. this fall, engaging in a transformative exchange of knowledge and ideas with the ...
(Date:6/23/2017)... ... , ... American Farmer, will feature Chr. Hansen, Inc (CHR Hansen) in an ... 2017. American Farmer airs Tuesdays at 8:30aET on RFD-TV. Check your local listings for ... Denmark in 1874 after a groundbreaking discovery of how to industrialize enzymes. Rooted in ...
(Date:6/23/2017)... TX (PRWEB) , ... June 23, 2017 , ... All-Star ... to residential and business clients throughout eastern Texas, is announcing the launch of a ... , Recent breast cancer statistics in the United States reveal that an estimated 252, ...
(Date:6/22/2017)... ... 22, 2017 , ... Plastic Surgery Associates is proud to report that founding ... year, research and information firm, Castle Connolly, releases their list of the most notable ... the 3rd time that Dr. Canales has been recognized by Castle Connolly. ...
Breaking Medicine News(10 mins):
(Date:6/19/2017)... , June 19, 2017  Researchers from DRUGSCAN ... that they will host a live, complimentary webinar titled, ... the benchtop to the real world" on Wednesday June ... This webinar will feature interviews with ... look into the manipulation techniques abusers use to prepare ...
(Date:6/14/2017)... June 14, 2017 The Bio Supply Management ... City of Fremont and the Biomedical Manufacturing ... industry in California by providing ... networking, and fostering workforce development. The primary focus of ... of start-ups, as well as small and mid-sized biomedical ...
(Date:6/11/2017)... June 10, 2017  Eli Lilly and Company (NYSE: ... Phase 3 studies of galcanezumab, an investigational treatment for ... data on several key secondary endpoints for galcanezumab compared ... these studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented ... meeting in Boston . ...
Breaking Medicine Technology: